The breast cancer susceptibility gene BARD1 (BRCA1-associated RING domain protein, MIM# 601593) acts with BRCA1 in DNA double-strand break (DSB) repair and also in apoptosis initiation. We screened 109 BRCA1/2 negative high-risk breast and/or ovarian cancer patients from North-Eastern Poland for BARD1 germline mutations using a combination of denaturing high-performance liquid chromatography and direct sequencing. We identified 16 different BARD1 sequence variants, five of which are novel. Three of them were suspected to be pathogenic, including a protein truncating nonsense mutation (c.1690C>T, p.Gln564X), a splice mutation (c.1315-2A>G) resulting in exon 5 skipping, and a silent change (c.1977A>G) which alters several exonic splicing enhancer motifs in exon 10 and results in a transcript lacking exons 2-9. Our findings suggest that BARD1 mutations may be regarded as cancer risk alleles and warrant further investigation to determine their actual contribution to non-BRCA1/2 breast and ovarian cancer families. © 2011 Springer Science+Business Media, LLC.
CITATION STYLE
Ratajska, M., Antoszewska, E., Piskorz, A., Brozek, I., Borg, Å., Kusmierek, H., … Limon, J. (2012). Cancer predisposing BARD1 mutations in breast-ovarian cancer families. Breast Cancer Research and Treatment, 131(1), 89–97. https://doi.org/10.1007/s10549-011-1403-8
Mendeley helps you to discover research relevant for your work.